genglob magazine

When patients are diagnosed with cancer, they have many thoughts, fears, and questions, and most want to learn more about their disease and treatment. There also are practical issues to consider—paying for treatment, finding transportation, keeping a job, and juggling family responsibilities. Patients are dealing with huge decisions and coping with stressful changes. Read the rest of this entry »

The combination of the immunomodulatory drug lenalidomide and the proteasome inhibitor bortezomib appears to be both safe and potentially able to induce durable responses in patients with relapsed or relapsed/refractory multiple myeloma, U.S. researchers report online in the Journal of Clinical Oncology. Read the rest of this entry »

October is officially tagged “Breast Cancer Awareness Month”. Of recent, there have been a lot of medical breakthroughs in the detection and treatment of Breast Cancer. Scientists have identified more accurate tools for screening younger women who are more likely to get the most dangerous forms and new strategies have also been developed for the treatment of newly diagnosed pregnant women.  Advanced research has led to the development of better, less toxic drugs to guard against recurrences. Read the rest of this entry »

“This novel proteasome inhibitor appears to improve response rates and
survival in patients with progressive multiple myeloma.” Read the rest of this entry »

Lung cancer has become more common in China in recent years. The rise in tobacco consumption is the most important factor in this increase. As is the case in many developing countries, indoor air pollution from poorly ventilated stoves is an additional risk factor, particularly for women. Read the rest of this entry »

Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, recently announced the availability of two new laboratory tests used to develop more effective cancer treatments.

These new tests are now being used in the clinical development of targeted therapies more likely to succeed in treating patients with cancer related to gene mutations. The lab tests, known as mutation assays identifies the genomic changes that occurs in each patient’s cancer and help researchers find the optimum individual treatment plan. This type of personalised medicine supports therapies that are safer, more effective and efficient, and minimise unnecessary or potentially harmful treatments. Read the rest of this entry »

Integration of Novel Agents Into Treatment Regimens for Patients With Advanced Non-Small-Cell Lung Cancer

Treatment options in non-small-cell lung cancer (NSCLC) have expanded recently due to the demonstration of efficacy of targeted agents alone or in combination with existing cytotoxic chemotherapies. Research with these approaches is ongoing, and the 2006 American Society of Clinical Oncology meeting featured presentations from studies of epidermal growth factor (EGFR) inhibitors and antiangiogenic agents, as well as on the use of other novel compounds. Read the rest of this entry »

Cancer (medical term: malignant neoplasm) is a class of diseases in which a group of cells display uncontrolled growth (division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). These three malignant properties of cancers differentiate them from benign tumors, which are self-limited, and do not invade or metastasize. Most cancers form a tumor but some, like leukemia, do not. The branch of medicine concerned with the study, diagnosis, treatment, and prevention of cancer is oncology. Cancer may affect people at all ages, even fetuses, but the risk for most varieties increases with age. Cancer causes about 13% of all human deaths. According to the American Cancer Society, 7.6 million people died from cancer in the world during 2007. Cancers can affect all animals. Read the rest of this entry »